Clinical trials: Psychological Disorders
Schizophrenia
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
A study to evaluate the efficacy and safety of an experimental drug (SEP-363856) in acutely psychotic adults with schizophrenia
- Trial name
- NCT02969382
- Testing
- SEP-363856
- Where
- 33 sites in United States, Hungary and 3 more
- Volunteers
- 245 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Stimulant Use Disorder
Smartphone Services for Stimulant Use Disorder
This study is testing two approaches to treating Stimulant Use Disorder, or problems with cocaine, crack, methamphetamine, etc. Stimulant Use Disorder is a national epidemic in the U.S.
- Trial name
- NCT07092059
- Testing
- Smartphone digital therapeutic system
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- DynamiCare Health
Premature Ejaculation
A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature Ejaculation
16448 is being investigated for the treatment of primary premature ejaculation (PE) using a novel mode of action. There are no approved therapies for premature ejaculation, and novel therapies are needed for this syndrome.
- Trial name
- NCT00537459
- Testing
- 16448
- Where
- Ireland
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder
Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder
To evaluate the efficacy of ramelteon for treatment of acute depressive episodes associated with Bipolar 1 Disorder.
- Trial name
- NCT01677182
- Testing
- Ramelteon
- Where
- 104 sites in United States, Bulgaria and 8 more
- Volunteers
- 535 people
- Sponsor
- Takeda
Schizophrenia
A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women
The purpose of this study is to assess the effect of cytochrome P450 isoenzyme 2D6 (CYP2D6) inhibition by quinidine on the pharmacokinetic (PK) parameters of a single dose SEP-380135 in healthy adult participants.
- Trial name
- NCT07305779
- Testing
- SEP-380135, Quinidine Gluconate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Type Dementia
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
The goal of this clinical study is to learn if the study drug DMB-I (INN: Latrepirdine) works to treat Alzheimer type dementia in adults. It will also learn about the safety of DMB-I (INN: Latrepirdine).
- Trial name
- NCT07251023
- Testing
- DMB-I (INN: Latrepirdine), Memantine Hydrochloride 20 MG
- Where
- 12 sites in Russia
- Volunteers
- 450 people
- Sponsor
- Bigespas LTD
Autism Spectrum Disorder
Characterization of a Clinical Subpopulation in Children With Autism Spectrum Disorder
This single-center, observational study is being conducted to identify a well-characterized subgroup within the ASD patient population, based on clinical symptoms and biosample analysis.
- Trial name
- NCT04600882
- Where
- United States
- Sponsor
- Stalicla SA
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Erectile Dysfunction
Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction.
This randomized, double blind, placebo controlled, multicentric, clinical study will assess the efficacy and safety of Udenafil (100 mg) tablets in patients suffering from erectile dysfunction(ED).
- Trial name
- NCT01305083
- Testing
- Udenafil
- Where
- 5 sites in Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Abdi Ibrahim Ilac San. ve Tic A.S.
Schizophrenia
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
- Trial name
- NCT01879722
- Testing
- TAK-063
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Takeda
Alzheimer's Disease
A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil
A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.
- Trial name
- NCT00672945
- Testing
- PRX-03140
- Where
- 38 sites in United States
- Volunteers
- 420 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Alcohol Aftereffects, Anxiety
A Clinical Study to Assess the Effects of JoyRise Recovery Powder on Mitigating Alcohol Aftereffects.
This study assesses the effectiveness of JoyRise Recovery Powder in reducing alcohol aftereffects, cognitive impairment, and anxiousness among participants aged 35-54 who consume alcohol.
- Conditions
- Alcohol Aftereffects, Anxiety, Cognitive Impairment
- Trial name
- NCT06575972
- Testing
- JoyRise Recovery Powder
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Joyrise
Excessive Daytime Sleepiness, Narcolepsy
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a histaminergic agent which therefore may improve alertness and awakeness in patients with excessive daytime sleepiness (EDS) associated…
- Trial name
- NCT01006122
- Testing
- PF-03654746
- Where
- 21 sites in United States
- Volunteers
- 95 people
- Sponsor
- Pfizer
Nicotine Addiction, Drug Addiction
Clinical Trial of Smoking Cessation Mobile Phone Program
The Sponsor is doing a research study to assess the effects of a smartphone program designed to help users smoke less and eventually quit. When participants join, their involvement in the core study will last 8 weeks.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT02656745
- Testing
- Mobile Smoking Cessation Solution
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
Efficacy of Bifeprunox in Patients With Schizophrenia
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
- Trial name
- NCT00658645
- Testing
- Bifeprunox, Quetiapine
- Where
- 38 sites in Bulgaria, China and 6 more
- Volunteers
- 227 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease
Safety, Tolerability, and Pharmacokinetics Study of NDX-1017
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects…
- Trial name
- NCT03298672
- Testing
- NDX-1017
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- LeonaBio
Opioid-Related Disorders
Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Buprenorphine HCl 8 mg tablet under fasted conditions.
- Trial name
- NCT00992095
- Testing
- buprenorphine hydrochloride
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Alzheimer Disease, Dementia
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05522387
- Testing
- XPro1595
- Where
- 4 sites in Australia
- Volunteers
- 11 people
- Sponsor
- Inmune Bio, Inc.
Opioid Overdose
Naloxone Nasal Spray Pharmacokinetic Study
This study aims to compare the pharmacokinetics of naloxone when administered as the Mitovie nasal spray (Test Product) and as a solution for injection (Comparator Product) administered intranasally using a mucosal atomization…
- Trial name
- NCT01622504
- Testing
- MVP005, Naloxone hydrochloride solution for injection with mucosal atomization device
- Where
- Jordan
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Mitovie Pharma Ltd
PTSD, Sleep Disturbance
Electrical Vestibular Nerve Stimulation (VeNS) as a Method of Sleep Management in People With PTSD
This double blind randomized controlled study will enroll 20 subjects and will be conducted remotely. The study will be randomized for an 8-week period with a 1:1 active to sham device allocation.
- Conditions
- PTSD, Sleep Disturbance, Insomnia
- Trial name
- NCT04780893
- Testing
- Modius Sleep
- Volunteers
- healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.